Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H19ClN4O2 |
| Molecular Weight | 394.854 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)CC1=NN(C2=CC=CC=C2)C(=O)C3=C1C4=CC=C(Cl)C=C4N3C
InChI
InChIKey=HJSQVJOROCIILI-UHFFFAOYSA-N
InChI=1S/C21H19ClN4O2/c1-24(2)18(27)12-16-19-15-10-9-13(22)11-17(15)25(3)20(19)21(28)26(23-16)14-7-5-4-6-8-14/h4-11H,12H2,1-3H3
| Molecular Formula | C21H19ClN4O2 |
| Molecular Weight | 394.854 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. | 2002 Jun |
|
| Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. | 2003 Sep |
|
| The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. | 2006 Jun |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:21:30 UTC 2023
by
admin
on
Fri Dec 15 16:21:30 UTC 2023
|
| Record UNII |
4K8W47WK2L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9930560
Created by
admin on Fri Dec 15 16:21:30 UTC 2023 , Edited by admin on Fri Dec 15 16:21:30 UTC 2023
|
PRIMARY | |||
|
4K8W47WK2L
Created by
admin on Fri Dec 15 16:21:30 UTC 2023 , Edited by admin on Fri Dec 15 16:21:30 UTC 2023
|
PRIMARY | |||
|
300000042533
Created by
admin on Fri Dec 15 16:21:30 UTC 2023 , Edited by admin on Fri Dec 15 16:21:30 UTC 2023
|
PRIMARY | |||
|
SSR-180,575
Created by
admin on Fri Dec 15 16:21:30 UTC 2023 , Edited by admin on Fri Dec 15 16:21:30 UTC 2023
|
PRIMARY | SSR-180,575 is a drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It has been shown to have neuroprotective and cardioprotective effects and to stimulate steroidogenesis of pregnenolone in the brain, which may be linked to its neuroprotective action. | ||
|
220448-02-2
Created by
admin on Fri Dec 15 16:21:30 UTC 2023 , Edited by admin on Fri Dec 15 16:21:30 UTC 2023
|
PRIMARY | |||
|
DTXSID10433007
Created by
admin on Fri Dec 15 16:21:30 UTC 2023 , Edited by admin on Fri Dec 15 16:21:30 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
SSR180575 shows high affinity (IC(50), 2.5-3.5 nM) and selectivity for the rat and human PBR and potently inhibits the in vivo binding of ((3)H)alpidem to PBR in the rat brain and spleen after oral or i.p. administration (ID(50), 0.1-0.3 mg/kg). In an experimental model of motoneuron degeneration induced by facial nerve axotomy in the immature rat, SSR180575 given i.p. or orally for 8 days rescued facial motoneurons, increasing their survival by 40 to 72% at 6 and 10 mg/kg p.o. b.i.d.
|
||
|
ACTIVE MOIETY |
The present work shows that SSR180575, a novel PBR ligand of potential interest in pathological cardiovascular indications, irreversibly and specifically binds with high affinity on both rat heart mitochondria and on a cell line transfected with the human PBR (Kd=1.95 +/- 0.22 and 4.58 +/- 0.83 nM, respectively). In conclusion, SSR180575 is a specific and potent PBR ligand which irreversible binding to PBR appears of high interest in various therapeutic indications where apoptosis occurs.
|
